AMERICAN RENAL SHAREHOLDERS HAVE AN OPPORTUNITY TO RECOVER THEIR INVESTMENT LOSSES

CLICK HERE TO VIEW THE FIRM RÉSUMÉ OF BERNSTEIN LIEBHARD LLP.

American Renal Associates Holdings, Inc.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of American Renal Associates Holdings, Inc. (NYSE: ARA) between August 10, 2016 and March 27, 2019. The lawsuit seeks to recover American Renal shareholders’ investment losses.

If you purchased shares of American Renal between August 10, 2016 and March 27, 2019 and would like to join the action, please click “Join Class Action” above.

INVESTOR ALERT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST AMERICAN RENAL ASSOCIATES HOLDINGS, INC. – ARA

March 29, 2019

New York, New York – Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of American Renal Associates Holdings, Inc. (“American Renal” or the “Company) (NYSE: ARA) between August 10, 2016 and March 27, 2019, both dates inclusive (the “Class Period”). The lawsuit, filed in the United States District Court for the District of New Jersey, seeks to recover damages for American Renal shareholders under the federal securities laws.

According to the lawsuit, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclosed that (1) American Renal had undisclosed material weaknesses in its internal controls over financial reporting as well as issues with the Company’s accounting process for revenue recognition and collections; (2) consequently, American Renal’s financial statements for the fiscal years 2014, 2015, 2016, and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018 were false and could not be relied upon; and, as a result, (3) American Renal’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff in the American Renal class action, you must move the court no later than May 28, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Joe Seidman

Bernstein Liebhard LLP

https://www.bernlieb.com

(877) 779-1414

seidman@bernlieb.com